Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

• R. López López ^[10] ; C. Camps Herrero ^[1] ; P. Khosravi-Shahi ^[2] ; V. Guillem Porta ^[3] ; A. Carrato Mena ^[4] ; J. Garcia-Foncillas ^[5] ; J. J. Cruz Hernández ^[6] ; P. Gascón Vilaplana ^[11] ; A. Antón Torres ^[7] ; E. Diaz-Rubio ^[8] ; M. Feyjoo Saus ; E. Aranda Aguilar ^[9]
  1. [1] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  2. [2] Hospital Universitario de Torrejón

     Hospital Universitario de Torrejón

     Torrejón de Ardoz, España

     
  3. [3] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  4. [4] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  5. [5] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  6. [6] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  7. [7] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  8. [8] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  9. [9] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  10. [10] Complejo Universitario de Santiago de Compostela, España
  11. [11] Fundació Clínic, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 5 (May 2018), 2018, págs. 613-618
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Purpose Breakthrough cancer pain (BTcP) has been shown to be a prevalent and poor prognostic factor for oncologic patients, which remain under diagnosed and undertreated. In 2012, the Spanish Society of Medical Oncology (SEOM) published a clinical practice guideline (CPG) for the treatment of cancer pain which specifically addressed the management of BTcP.

    Methods Fundación ECO designed a qualitative study using an Internet-based survey to investigate the attitudes toward, compliance with, and use of SEOM Guideline.

    Results A total of 83 oncologists with a mean experience of 13 years responded. Overall, 82% were aware of different guidelines to manage BTcP. Notably, attitudes toward guidelines were highly positive and there was nearly unanimous agreement that CPG provided the best scientific evidence available (99%), on the minimum information to be gathered for the medical history (100%), on the need for a specific treatment for BTcP (100%), and fentanyl as the first-choice drug (99%). Interestingly, there were discrepancies between what oncologists agreed with and what they do in clinical practice. In fact, 87.6% declare full compliance with SEOM guideline, although adherence to registration of BTcP data in medical records ranged from 30.1 to 91.6% (mean 64.5%); therapeutic management compliance was higher ranging from 75.9 to 91.6%. Main barriers identified were time pressure together with vague statements and limited dissemination of the guidelines.

    Conclusion Despite oncologist’s clinical practice is increasingly guided by GPC, it suffers from limited compliance, at least in part due to suboptimal statements. Improved dissemination and education are needed to enhance guideline implementation.